```
=> d his

     (FILE 'HOME' ENTERED AT 13:29:19 ON 27 MAY 2009)

     FILE 'CAPLUS' ENTERED AT 13:29:30 ON 27 MAY 2009
                E WANG JIABING/AU
                SET EXPAND CONTINUOUS
L1           55 S E1-E3
L2            5 S L1 AND ANDROGENS/IT
L3            2 S L2 AND (PY<2004 OR AY<2004 OR PRY<2004)
                E MCVEAN CAROL/AU
L4           11 S E16
L5            1 S L4 AND ANDROGENS/IT
L6            5 S L1 AND ANDROGENS/CT
L7            2 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
L8            0 S L7 NOT L3

     FILE 'REGISTRY' ENTERED AT 13:33:32 ON 27 MAY 2009
                E 153114-66-0/RN
L9            1 S E27

     FILE 'CAPLUS' ENTERED AT 13:33:55 ON 27 MAY 2009
L10           6 S L9
L11           6 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'REGISTRY' ENTERED AT 13:35:21 ON 27 MAY 2009
                E 828241-49-2/RN
L12           1 S E39
                E 153114-77-3/RN
L13           1 S E51
                E 828241-50-5/RN
L14           1 S E63
                E 827581-88-4/RN
L15           1 S E75

     FILE 'CAPLUS' ENTERED AT 13:37:18 ON 27 MAY 2009
L16           1 S L15

     FILE 'REGISTRY' ENTERED AT 13:38:07 ON 27 MAY 2009
                E 827582-67-2/RN
L17           1 S E87

     FILE 'CAPLUS' ENTERED AT 13:38:32 ON 27 MAY 2009
L18           1 S L17

     FILE 'REGISTRY' ENTERED AT 13:38:57 ON 27 MAY 2009
                E 827583-17-5/RN
L19           1 S E99

     FILE 'CAPLUS' ENTERED AT 13:39:19 ON 27 MAY 2009
L20           1 S L19

     FILE 'REGISTRY' ENTERED AT 13:39:41 ON 27 MAY 2009
                E 827581-68-9/RN
L21           0 S E111
                E 827584-68-9/RN
L22           1 S E123
```

```
     FILE 'CAPLUS' ENTERED AT 13:40:33 ON 27 MAY 2009
L23           1 S L22

     FILE 'REGISTRY' ENTERED AT 13:40:54 ON 27 MAY 2009
                 E 827584-77-0/RN
L24           1 S E135

     FILE 'CAPLUS' ENTERED AT 13:41:19 ON 27 MAY 2009
L25           1 S L24


L10  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   867345-83-3  REGISTRY
CN   1H-Indeno[5,4-f]quinoline-7-acetic acid,
     11-chloro-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-
1,4a,6a-
     trimethyl-2-oxo-, (4aR,4bS,6aR,7R,9aS,9bS)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C21 H30 Cl N O3
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PREP (Preparation); RACT (Reactant or
reagent)

Absolute stereochemistry.
```




```
=> s l10
L11           1 L10

=> d l11 ti abs ibib hitind

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of 17β-acetamide-4-azasteroids as androgen receptor
     modulators
GI
```



I



II

AB Azasteroids of structural formula I [X, Y = H, halo, OH, alkoxy, hydroxymethyl, alkyl; R1 = H, acyl, OH, alkyl, etc.; R1R4 = 5-6 membered ring; R2 = H, alkyl; R3 = aryl, alkylaryl, heteroaryl, alkyl, etc.; R2R3 = 5-6 membered ring; R4 = halo, alkyl, cyclopropa, oxo, etc.] are prepared as modulators of the androgen receptor (AR) in a tissue selective manner. These compds. are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents. Thus, II was prepared Some of the compds. had IC50 values of 1 μM or less in an assay for endogenously expressed AR.

ACCESSION NUMBER: 2005:1154379 CAPLUS Full-text
DOCUMENT NUMBER: 143:406045
TITLE: Preparation of 17β-acetamide-4-azasteroids as androgen receptor modulators
INVENTOR(S): Wang, Jiabing; Mcvean, Carol A.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005099707	A1	20051027	WO 2005-US11537	20050404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

```
GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP,
KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NA,
             NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL,
             SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA,
             ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,
PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML,
             MR, NE, SN, TD, TG

=> s l18
L19          1 L18

=> d his

     (FILE 'HOME' ENTERED AT 14:01:55 ON 27 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 14:02:12 ON 27 MAY 2009
                E 867345-26-4/RN
                SET EXPAND CONTINUOUS
L1            1 S E3

     FILE 'REGISTRY' ENTERED AT 14:04:07 ON 27 MAY 2009
L2              STRUCTURE UPLOADED
L3            2 S L2 SSS SAM
L4           30 S L2 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:04:41 ON 27 MAY 2009
L5            1 S L4

     FILE 'BIOSIS' ENTERED AT 14:05:00 ON 27 MAY 2009
L6            0 S L4

     FILE 'MARPAT' ENTERED AT 14:05:12 ON 27 MAY 2009
L7            0 S L4

     FILE 'REGISTRY' ENTERED AT 14:12:21 ON 27 MAY 2009
L10           1 S 867345-83-3/RN
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 14:12:33 ON 27 MAY 2009
L11           1 S L10

     FILE 'REGISTRY' ENTERED AT 14:13:13 ON 27 MAY 2009
L12           1 S 867345-82-2/RN
```

```
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 14:13:33 ON 27 MAY 2009
L13           1 S L12

     FILE 'REGISTRY' ENTERED AT 14:13:46 ON 27 MAY 2009
L14           1 S 867345-81-1/RN
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 14:13:58 ON 27 MAY 2009
L15           1 S L14

     FILE 'REGISTRY' ENTERED AT 14:14:15 ON 27 MAY 2009
L16           1 S 867345-77-5/RN
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 14:14:25 ON 27 MAY 2009
L17           1 S L16

     FILE 'REGISTRY' ENTERED AT 14:14:44 ON 27 MAY 2009
L18           1 S 867345-26-4/RN
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 14:14:56 ON 27 MAY 2009
L19           1 S L18

d his

     (FILE 'HOME' ENTERED AT 09:41:19 ON 28 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 09:41:31 ON 28 MAY 2009
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS FULL
L3              STRUCTURE UPLOADED
L4          476 S L3 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:43:45 ON 28 MAY 2009
L5          233 S L4
L6           48 S L5 AND ANDROGENS/IT
L7           26 S L6 AND (PY,2004 OR AY<2004 OR PRY,2004)
L8           15 S L5 AND ANDROGEN RECEPTORS/IT
L9           12 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10          10 S L9 NOT L7
L11           3 S L5 AND HORMONE REPLACEMENT THERAPY/IT
L12           1 S L11 AND (PY<2004 OR AY,2004 OR PRY<2004)
L13           1 S L11 AND (PY<2004 OR AY<2004 OR PRY<2004)
L14           0 S L13 NOT L7
L15           3 S L5 AND HYPOGONADISM/IT
L16         207 S L5 NOT L7
L17           1 S L15 NOT L7
L18           1 S L17 AND (PY<2004 OR AY<2004 OR PRY<2004)
L19           7 S L5 AND CANCER/IT
```

```
L20           6 S L19 AND (PY<2004 OR AY<2004 OR PRY<2004)
L21           5 S L20 NOT L7
L22           4 S L5 AND OSTEOPOROSIS/IT
L23           3 S L22 AND (PY<2004 OR AY,2004 OR PRY<2004)
L24           3 S L22 AND (PY<2004 OR AY<2004 OR PRY<2004)
L25           1 S L24 NOT L7
L26           0 S L5 AND REPRODUCTION/IT
L27           7 S L5 AND MUSCLE/IT
L28           4 S L27 AND (PY<2004 OR AY<2004 OR PRY<2004)
L29           2 S L28 NOT L7
L30           0 S L5 AND NEURODEGENERATION/IT

d his

     (FILE 'HOME' ENTERED AT 10:58:49 ON 28 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 10:59:02 ON 28 MAY 2009
                E 137099-09-3/RN
                SET EXPAND CONTINUOUS
L1            1 S E3
                E 188754-68-9/RN
L2            1 S E15
                E 188754-70-3/RN
L3            1 S E27
                E 73671-86-0/RN
L4            1 S E39
                E 158522-92-0/RN
L5            1 S E51
                E 158522-93-1/RN
L6            1 S E63

     FILE 'REGISTRY' ENTERED AT 11:06:15 ON 28 MAY 2009
                E 867345-26-4/RN
L7            1 S E75
L8              STRUCTURE UPLOADED

L8      STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8              STR
```




```
L9            0 S L8 SSS FULL
L10             STRUCTURE UPLOADED
```

L11 2 S L10 SSS FULL

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



FILE 'CAPLUS' ENTERED AT 11:09:43 ON 28 MAY 2009
L12 6 S L11
L13 6 S L12 AND (PY<2004 OR AY<2004 OR PRY<2004)

L13 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
GI



I



II

AB New 7β-substituted 4-aza-5α-androstan-3-ones of formula I [R = H, Me, Et; A = aminoalkyl, alkyl, alkoxy, etc.] and related compds. are prepared as 5α-reductase inhibitors. Thus, II was prepared from 20-hydroxy-7β-methyl-5α-4-azapregnan-3-one and dimethoxycyclohexane in 2 steps.

ACCESSION NUMBER: 1998:62248 CAPLUS Full-text
DOCUMENT NUMBER: 128:140893
ORIGINAL REFERENCE NO.: 128:27727a,27730a
TITLE: Preparation of 7β-substituted-4-aza-5α-androstan-3-ones as

5α-reductase inhibitors

INVENTOR(S): Bakshi, Raman K.; Rasmusson, Gary H.; Tolman, Richard L.; Patel, Gool F.; Harris, Georgianna S.; Graham, Donald W.; Witzel, Bruce E.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: U.S., 95 pp., Cont.-in-part of U.S. Ser. No. 886,572, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5710275	A	19980120	US 1995-341602	19950403 <--
WO 9323420	A1	19931125	WO 1993-US4643	19930514 <--

W: BB, BG, BR, CZ, FI, HU, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US

RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
US 1992-886572	B2	19920520 <--
WO 1993-US4643	W	19930514 <--

L13 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of substituted 4-aza-3-oxo-steroids for use as 5α-reductase inhibitors

GI



I

AB Steroids such as 4-aza-5α-androstan-ones I [1,2-, 5,6-saturated or unsatd.; R4 = H, Me, Et; R7 = R7a = H, OH, alkyl, alkenyl, carbamoyloxy, carboxy, etc.; R7R7a = oxo, cycloalkyl, etc.; R16 = R16a = H, alkyl; R16R16a = cycloalkenyl; R17 = R17a = H, acyl, carbamoyl, aminoalkyl, alkyl, etc.; R17R17a = oxo, etc.] were prepared as 5α-reductase inhibitors for treatment of hyperandrogenic conditions. Thus, 4-methyl-17β-

(trimethylacetamido)-5α-4-azaandrostan-3-one was prepared via oximation of 4-methyl-3-oxo-5α-4-azaandrostan-17- carboxaldehyde, hydrogenation to form the corresponding amine followed by N-acylation with Me3CCO2Cl. The prepared compds. were tested for inhibition of human prostatic and scalp 5α-reductase, however, activities for specific compds. were not presented.

ACCESSION NUMBER: 1997:776029 CAPLUS Full-text
DOCUMENT NUMBER: 128:61680
ORIGINAL REFERENCE NO.: 128:12090h,12091a
TITLE: Preparation of substituted 4-aza-3-oxo-steroids for use as 5α-reductase inhibitors
INVENTOR(S): Durette, Philippe L.; Hagmann, William; Rasmusson, Gary H.; Tolman, Richard L.; Kopka, Ihor E.; Sahoo, Soumya P.; Esser, Craig K.; Steinberg, Nathan G.; Graham, Donald W.; Witzel, Bruce E.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 139 pp., Cont.-in-part of U.S. Ser. No. 886,537, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5693809	A	19971202	US 1995-338571	19950512 <--
PRIORITY APPLN. INFO.:			US 1992-886537	B2 19920520 <--

L13 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI 17-Ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5α-reductase inhibitors
GI



I

AB Title compds. I [R = H, Me, Et; R1 = H, Me; R2 = acyl, carbamoyl, carboxylic ester; n = 0-10] were prepared for use as 5α-reductase inhibitors. Thus, 3-oxo-4-methyl-N-phenyl-4-aza-5α-pregnane-21-carboxylic acid was converted to its anilide by reaction with PhNH2 in presence of Me2CHCOCl, N-methylmorpholine, and DMAP.

ACCESSION NUMBER: 1996:323793 CAPLUS Full-text
DOCUMENT NUMBER: 125:58853
ORIGINAL REFERENCE NO.: 125:11337a,11340a
TITLE: 17-Ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5α-reductase inhibitors
INVENTOR(S): Graham, Donald W.; Aster, Susan D.; Hagmann, William; Tolman, Richard L.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 886,021, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5510485	A	19960423	US 1994-335792	19941110 <--
PRIORITY APPLN. INFO.:			US 1992-886021 B2	19920520 <--

L13 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI preparation of substituted 4-aza-5a-androstanones as 5α-reductase inhibitors
GI



I

AB 4-Aza-5α-androstan-3-ones [I; R = H, Me, Et; T1, T2 = H, C1-6 alkyl, T1T2 = C1-6 alkylidene; R1, R2 = H, C1-4 alkyl, C2-4 alkenyl, CO2H, OH, CH2CO2H, carbamoyloxy, etc., R1R2 = O; A = (substituted) hydrocarbyl, carbamoyl, etc.; a, b, e = single or double bond] and related compds., effective at 0.01-7 mg/kg as 5α-reductase inhibitors in treating benign prostatic hypertrophy, prostatitis, prostatic carcinoma, hyperandrogenic conditions,

etc., are prepared Thus, oximation of 4-methyl-3-oxo-4-aza-5α-androstane-17β-carboxaldehyde and subsequent reduction by H over PtO2 gave the corresponding 17β-(aminomethyl) derivative Acylation of this aminomethyl compound with MeO2C(CH2)7COCl in pyridine/CH2Cl2 gave 17β-[[[8-(methoxycarbonyl)octanoyl]amino]methyl]-4-methyl-4-aza- 5α-androstan-3-one.

ACCESSION NUMBER: 1995:266948 CAPLUS Full-text
DOCUMENT NUMBER: 122:56297
ORIGINAL REFERENCE NO.: 122:10919a,10922a
TITLE: preparation of substituted 4-aza-5a-androstanones as
5α-reductase inhibitors
INVENTOR(S): Durette, Philippe L.; Hagmann, William; Rasmusson,
Gary H.; Tolman, Richard L.; Kopka, Ihor E.; Sahoo,
Soumya P.; Esser, Craig K.; Steinberg, Nathan G.;
Graham, Donald W.; Witzel, Bruce E.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 533 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323039	A1	19931125	WO 1993-US4734	19930518 <--
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9342519	A	19931213	AU 1993-42519	19930518 <--

PRIORITY APPLN. INFO.: US 1992-886537 A2 19920520 <--
WO 1993-US4734 A 19930518 <--

L13 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI preparation of 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
GI



I

AB The title compds. [I; R = H, Me, Et; R1 = H; R2 = substituted C1-4 alkyl, C2-4 alkenyl, OH, CO2H, ester residue, CH2CO2H, etc., R1R2 = O; A = oxo, substituted alkyl, etc.; a, b = saturated or unsatd. (α-H is absent)], useful in treating male pattern baldness, benign prostatic hypertrophy, prostatic carcinoma, prostatitis, etc. at 0.01-7 mg/kg-day, are prepared Oxidative cleavage of 17β-[(tert-butyldimethylsilyl)oxy]-7β- methylandrost-4-en-3-one with NaIO4 and KMnO4 in tert-BuOH at 80° gave 17β-[(tert-butyldimethylsilyl)oxy]-7β-methyl-5-oxo-A-nor- 3,5-secoandrostan-3-oic acid, which was heated with MeNH2.HCl and NaOAc in HOCH2CH2OH at 180° to give the aza analog I (R = R2 = Me, R1 = H, A = β-tert-BuSiMe2O, a = saturated, b = unsatd., α-H absent).

ACCESSION NUMBER: 1994:680955 CAPLUS Full-text
DOCUMENT NUMBER: 121:280955
ORIGINAL REFERENCE NO.: 121:51307a,51310a
TITLE: preparation of 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
INVENTOR(S): Bakshi, Raman K.; Rasmusson, Gary H.; Tolman, Richard L.; Patel, Gool F.; Harris, Georgianna; Graham, Donald W.; Witzel, Bruce E.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 229 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 572166	A1	19931201	EP 1993-303882	19930519 <--
EP 572166	B1	19970813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
IL 105715	A	19970713	IL 1993-105715	19930517 <--
CA 2096616	A1	19931121	CA 1993-2096616	19930519 <--
AU 9338698	A	19931125	AU 1993-38698	

19930519 <--
AU 662224 B2 19950824
ZA 9303497 A 19931214 ZA 1993-3497
19930519 <--
CN 1087092 A 19940525 CN 1993-107704
19930519 <--
EP 778284 A2 19970611 EP 1996-202933
19930519 <--
EP 778284 A3 19970813
EP 778284 B1 20031126

L13 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of 17-ester, -amide, and -ketone derivatives of 3-oxo-4-azasteroids as testosterone 5α-reductase inhibitors
GI



I

AB Title compds. [I; R = H, Me, Et; R4 = COR1, CONHR2, CO2R3; R1 = (hetero)aryl; R2 = substituted Ph, (substituted)heteroaryl, cycloalkyl; R3 = cycloalkyl, (substituted)aryl; R20 = H, Me; n = 0-10; dashed line = optional bond] were prepared as testosterone 5α-reductase inhibitors (no data). Thus,4-methyl-17β-trifluoromethylsulfonyloxy-4-aza- 5α-androst-16-en-3-one was condensed with HC.tplbond.CCH2CH2CO2Me and the reduced product saponified to give I (R = Me, R4 CO2H, R20 = H, n = 3).

ACCESSION NUMBER: 1994:134931 CAPLUS Full-text
DOCUMENT NUMBER: 120:134931
ORIGINAL REFERENCE NO.: 120:23791a,23794a
TITLE: Preparation of 17-ester, -amide, and -ketone derivatives of 3-oxo-4-azasteroids as testosterone 5α-reductase inhibitors
INVENTOR(S): Graham, Donald W.; Aster, Susan D.; Hagmann, William; Tolman, Richard L.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
     ---------------     ----   --------    --------------------   ----
----
     WO 9323051           A1     19931125    WO 1993-US4631
19930517 <--
          W:  AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN,
MW, NO,
              NZ, PL, RO, RU, SD, SK, UA, US
          RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE,
              BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
     AU 9342505           A      19931213    AU 1993-42505
19930517 <--
     AU 674145            B2     19961212
     EP 641209            A1     19950308    EP 1993-911331
19930517 <--
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL,
PT, SE
     JP 07508033          T      19950907    JP 1993-503779
19930517 <--
PRIORITY APPLN. INFO.:                      US 1992-886021      A2
19920520 <--
                                            WO 1993-US4631      A
19930517 <--
```